Purpose of Review <p>This comprehensive analysis evaluates the potential of exosome therapy for treating temporomandibular joint osteoarthritis (TMJ OA), a degenerative disease characterized by cartilage degradation, bone remodeling, and chronic inflammation. Although existing treatment methods are effective, they often fall short in restoring damaged joint tissues, highlighting the need for innovative therapies approaches.</p> Recent Findings <p>Exosomes, which are small extracellular vesicles derived from various cell types, including mesenchymal stem cells, play a key role in intercellular communication and tissue repair. They enhance matrix synthesis, restore mitochondrial function, promote cell proliferation, and modulate inflammatory responses, making them promising candidates for temporomandibular joint osteoarthritis therapy. Intra-articular injections of exosomes have demonstrated positive outcomes in animal studies, including reduced inflammation, enhanced cartilage and bone healing, and improved joint function. Compared to conventional therapies, exosome therapy offers lower immunogenicity. Moreover, there is no risk of tumor formation associated with this therapy.</p> Summary <p>While the preliminary results are promising, additional research is necessary to achieve a thorough understanding of the mechanisms involved and to confirm the effectiveness of exosome therapy in human clinical trials. This review emphasizes the potential of exosome therapy to revolutionize the treatment of temporomandibular joint osteoarthritis, with the promise of improved clinical outcomes for patients.</p>